{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-100239","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.266933+00:00","generated_at":"2026-05-31T04:29:26.755821+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Brainstorm Cell shareholders OK 150M authorized share increase, reverse split, equity plan boost","bullets":["Stockholders approved increasing authorized common shares from 100M to 250M.","Board authorized to effect reverse stock split of 1:5 to 1:15 at any time before Sept 16, 2025.","Equity plan share pool increased by 8M shares to 13.6M; each plan extended to 2034.","All seven director nominees elected; Brightman Almagor Zohar & Co. ratified as auditor.","Advisory vote on executive compensation approved with a 3-year frequency for future votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-100239","json":"https://secwatch.observer/filing/0001104659-24-100239.json","markdown":"https://secwatch.observer/filing/0001104659-24-100239.md","text":"https://secwatch.observer/filing/0001104659-24-100239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/0001104659-24-100239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:29:26.755821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}